Omeros eyes up 2014 launch for ophthalmic agent but what’s the opportunity?
This article was originally published in Scrip
Omeros Corporation continues to stay on track with planned US and EU submissions for its ophthalmology product, OMS302, in the first half of next year and mid-2013 respectively, after reporting positive data from a second pivotal Phase III trial of the agent. The company is hoping for market launches in 2014.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.